GVS-111 prevents oxidative damage and apoptosis in normal and Down's syndrome human cortical neurons

International Journal of Developmental Neuroscience

Volumn 21, Issue 3, 2003, Pages 117-124

  Pelsman, Alejandra ^a   Hoyo Vadillo, Carlos ^a,b   Gudasheva, Tatiana A ^c   Seredenin, Sergei B ^c   Ostrovskaya, Rita U ^c   Busciglio, Jorge ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

Alzheimer's disease; Dipeptides; Down's syndrome; GVS 111; Lipid peroxidation; Neurodegeneration; Neuroprotection; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; FERROUS SULFATE; GALLIC ACID PROPYL ESTER; GVS 111; HYDROGEN PEROXIDE; N TERT BUTYL 2 SULFOPHENYLNITRONE; NOOTROPIC AGENT; PIRACETAM; PYRROLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN CELL; CELL STRUCTURE; CELL SURVIVAL; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOWN SYNDROME; DRUG INHIBITION; DRUG MECHANISM; DRUG SCREENING; EXPERIMENTAL MODEL; HUMAN; HUMAN TISSUE; IC 50; INCUBATION TIME; LIPID PEROXIDATION; MENTAL DEFICIENCY; NERVE CELL DEGENERATION; NEUROPROTECTION; OXIDATIVE STRESS; PRIORITY JOURNAL; TISSUE CULTURE;

EID: 0037403824     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0736-5748(03)00031-5     Document Type: Article

References (36)

1. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38:1995;357-366.
2. Behl C., Davis J.B., Lesley R., Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell. 77:1994;817-827.
3. Brandao F., Paula-Barbosa M.M., Cadete-Leite A. Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. Alcohol. 12:1995;279-288.
4. Brandao F., Cadete-Leite A., Andrade J.P., Madeira M.D., Paula-Barbosa M.M. Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. Alcohol. 13:1996;239-249.
5. Busciglio J., Yankner B.A. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature. 378:1995;776-779.
6. Busciglio J., Yeh J., Yankner B.A. Beta-amyloid neurotoxicity in human cortical culture is not mediated by excitotoxins. J. Neurochem. 61:1993;1565-1568.
7. Busciglio J., Andersen J.K., Schipper H.M., Gilad G.M., McCarty R., Marzatico F., Toussaint O. Stress, aging, and neurodegenerative disorders. Molecular mechanisms. Ann. N. Y. Acad. Sci. 851:1998;429-443.
8. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., Yankner B.A. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron. 33:2002;677-688.
9. Cathcart R., Schwiers E., Ames B.N. Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal. Biochem. 134:1983;111-116.
10. de Haan J.B., Wolvetang E.J., Cristiano F., Iannello R., Bladier C., Kelner M.J., Kola I. Reactive oxygen species and their contribution to pathology in Down's syndrome. Adv. Pharmacol. 38:1997;379-402.
11. Fadok V.A., Voelker D.R., Campbell P.A., Cohen J.J., Bratton D.L., Henson P.M. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 148:1992;2207-2216.
12. Giurgea C. Vers une pharmacologie de l'activite integrative du cerveau: tentative du concept nootrope en psychopharmacologie. Actualites Pharmacol. 25:1972;115-156.
13. Goodman Y., Mattson M.P. Ceramide protects hippocampal neurons against excitotoxic and oxidative insults, and amyloid beta-peptide toxicity. J. Neurochem. 66:1996;869-872.
14. Goodman Y., Bruce A.J., Cheng B., Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 66:1996;1836-1844.
15. Gouliaev A.H., Senning A. Piracetam and other structurally related nootropics. Brain Res. Rev. 19:1994;180-222.
16. Grace E., Busciglio J. Aberrant activation of focal adhesion proteins mediates fibrillar Aβ-induced neuronal dystrophy. J. Neurosci. 23:2003;493-502.
17. Grace E., Rabiner C., Busciglio J. Characterization of neuronal dystrophy induced by fibrillar amyloid β: implications for Alzheimer's disease. Neuroscience. 114:2002;265-273.
18. Gudasheva T., Voronina T., Ostrovskaya R., Rozantsev G., Vasilevich N., Trophimov S., Kravchenko E., Skoldinov A., Seredenin S. Synthesis and antiamnestic activity of a series of N-acylprolyl-containing dipeptides. Eur. J. Med. Chem. 31:1996a;151-157.
19. Gudasheva T.A., Boyko S.S., Akparov V., Ostrovskaya R.U., Skoldinov S.P., Rozantsev G.G., Voronina T.A., Zherdev V.P., Seredenin S.B. Identification of a novel endogenous memory facilitating cyclic dipeptide cyclo-prolylglycine in rat brain. FEBS Lett. 391:1996b;149-152.
20. Juurlink B.H., Husain J. Hyperthermic injury of oligodendrocyte precursor cells: implications for dysmyelination disorders. Brain Res. 641:1994;353-356.
21. Kedziora J., Bartosz G. Down's syndrome: a pathology involving the lack of balance of reactive oxygen species. Free Radic. Biol. Med. 4:1988;317-330.
22. Kovalenko L.P., Miramedova M.G., Alekseeva S.V., Gudasheva T.A., Ostrovskaia R.U., Seredenin S.B. Anti-inflammatory properties of Noopept (dipeptide nootropic agent GVS-111). Exp. Clin. Pharmacol. (Russia). 65:2002;53-55.
23. Lysenko A.V., Uskova N.I., Ostrovskaia R.U., Gudasheva T.A., Voronina T.A. Dipeptide nootropic agent GVS-111 prevents accumulation of the lipid peroxidation products during immobilization. Exp. Clin. Pharmacol. (Russia). 60:1997;15-18.
24. Martin S.J., Reutelingsperger C.P., McGahon A.J., Rader J.A., van Schie R.C., LaFace D.M., Green D.R. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J. Exp. Med. 182:1995;1545-1556.
25. Mattson M.P., Chan S.L. Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits. J. Mol. Neurosci. 17:2001;205-224.
26. Ostrovskaya R.U., Romanova G.A., Trofimov S.S., Gudasheva T.A., Voronina T.A., Halikas J.A., Seredenin S.B. The novel substituted acylproline-containing dipeptide, GVS-111, promotes the restoration of learning and memory impaired by bilateral frontal lobectomy in rats. Behav. Pharmacol. 8:1997;261-268.
27. Ostrovskaya R., Gudasheva T., Andreeva N., Victorov I. Neurometabolic effects of prolyl-containing cognition enhancer GVS-111 suggests its effectiveness in Alzheimer disease. Neuroscience Lett. (Suppl.). 51:1998;S31.
28. Ostrovskaya R., Romanova G., Barskov I., Shanina E., Gudasheva T., Victorov I., Voronina T., Seredin S. Memory restoring and neuroprotective effects of proline-containing dipeptide GVS-111 in photochemical stroke model. Behav. Pharmacol. 10:1999;549-553.
29. Ostrovskaya R.U., Mirsoev T., Firova F., Trofimov S., Gudasheva T.A., Grechenko T., Gutirchik E., Barkova E. Behavioral and electrophysiological analysis of the cholino-positive effect of the nootropic acyl-prolyl containing dipeptide, GVS-111. Exp. Clin. Pharmacol. (Russia). 64:2001a;11-14.
30. Ostrovskaya R.U., Mirsoev T.K., Romanova G.A., Gudasheva T.A., Kravchenko E.V., Trofimov C.C., Voronina T.A., Seredenin S.B. Proline-containing dipeptide GVS-111 retains nootropic activity after oral administration. Bull. Exp. Biol. Med. 132:2001b;959-962.
31. Romanova G., Ostrovskaya R., Gudasheva T. Novel substituted acyl-prolyl dipeptide, GVS-111, diminished cognitive impairment on the model of brain compression in rats. Eur. Neuropsychopharmacol. 6(S4):1996;100.
32. Ross M.H., Galaburda A.M., Kemper T.L. Down's syndrome: is there a decreased population of neurons? Neurology. 34:1984;909-916.
33. Shi B., Raina J., Lorenzo A., Busciglio J., Gabuzda D. Neuronal apoptosis induced by HIV-1 Tat protein and TNF-α: potentiation of neurotoxicity mediated by oxidative stress and implications for HIV-1 dementia. J. Neurovirol. 4:1998;281-290.
34. Solntseva E.I., Bukanova J.V., Ostrovskaya R.U., Gudasheva T.A., Voronina T.A., Skrebitsky V.G. The effects of Piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels. Gen. Pharmacol. 29:1997;85-89.
35. Vaglenova J., Vesselinov Petkov V. Can nootropic drugs be effective against the impact of ethanol teratogenicity on cognitive performance? Eur. Neuropsychopharmacol. 11:2001;33-40.
36. Yankner B.A. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron. 16:1996;921-932.